Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/48995 |
Resumo: | Corrections: In this paper by Ranzani and colleagues (BMJ 2021;374:n2015, doi:10.1136/bmj.n2015, published 20 August 2021), author Edlaine Faria de Moura Villela should have been shown affiliated with address 5 [not 6], the Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil. |
id |
CRUZ_a8e1434076455fa5b40e64e08cd57f13 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/48995 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Ranzani, Otavio T.Hitchings, Matt D. T.Dorion, MuriloD'Agostini, Tatiana LangPaula, Regiane Cardoso dePaula, Olivia Ferreira Pereira deVillela, Edlaine Faria de MouraTorres, Mario Sergio ScaramuzziniOliveira, Silvano Barbosa deSchulz, WadeAlmiron, MariaSaid, RodrigoOliveira, Roberto Dias deSilva, Patricia Vieira daAraújo, Wildo Navegantes deGorinchteyn, Jean CarloAndrews, Jason R.Cummings, Derek A. T.Ko, Albert I.Croda, Julio2021-09-06T14:30:38Z2021-09-06T14:30:38Z2021RANZANI, Otavio T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. British Medical Journal, v. 374, n. 2015, p. 1-12, 20 Aug. 2021.1759-2151https://www.arca.fiocruz.br/handle/icict/4899510.1136/bmj.n20150959-8138Corrections: In this paper by Ranzani and colleagues (BMJ 2021;374:n2015, doi:10.1136/bmj.n2015, published 20 August 2021), author Edlaine Faria de Moura Villela should have been shown affiliated with address 5 [not 6], the Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.Instituto de Salud Global de Barcelona. Barcelona, España / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Instituto do Coração. Divisão de Pneumologia. São Paulo, SP, Brasil.University of Florida. College of Public Health & Health Professions. Department of Biostatistics. Gainesville, FL, USA.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.Governo do Estado de São Paulo. Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças. São Paulo, SP, Brasil.Governo do Estado de São Paulo. Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças. São Paulo, SP, Brasil.Governo do Estado de São Paulo. Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças. São Paulo, SP, Brasil.Governo do Estado de São Paulo. Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças. São Paulo, SP, Brasil.Prefeitura de Manaus. Secretaria Municipal de Saúde de Manaus. Manaus, AM, Brasil.Organização Pan-Americana da Saúde. Brasília, DF, Brasil / Universidade de Brasília. Brasília, DF, Brasil.Yale University School of Medicine. Department of Laboratory Medicine. New Haven, CT, USA.Organização Pan-Americana da Saúde. Brasília, DF, Brasil.Organização Pan-Americana da Saúde. Brasília, DF, Brasil.Universidade Estadual de Mato Grosso do Sul. Dourados, MS, Brasil.Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.Organização Pan-Americana da Saúde. Brasília, DF, Brasil / Universidade de Brasília. Brasília, DF, Brasil / Conselho Nacional de Desenvolvimento Científico e Tecnológico. Instituto Nacional de Ciência e Tecnologia para Avaliação de Tecnologias em Saúde. Porto Alegre, RS, Brasil.Governo do Estado de São Paulo. Secretaria de Estado da Saúde. São Paulo, SP, Brasil.Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil.OBJECTIVE: To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, Brazil during widespread circulation of the gamma variant. DESIGN: Test negative case-control study. SETTING: Community testing for covid-19 in São Paulo state, Brazil. PARTICIPANTS: 43774 adults aged ≥70 years who were residents of São Paulo state and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARSCoV-2 from 17 January to 29 April 2021. 26433 cases with symptomatic covid-19 and 17622 test negative controls with covid-19 symptoms were formed into 13283 matched sets, one case with to up to five controls, according to age, sex, self-reported race, municipality of residence, previous covid-19 status, and date of RT-PCR test (±3 days). INTERVENTION: Vaccination with a two dose regimen of CoronaVac. MAIN OUTCOME MEASURES: RT-PCR confirmed symptomatic covid-19 and associated hospital admissions and deaths. RESULTS: Adjusted vaccine effectiveness against symptomatic covid-19 was 24.7% (95% confidence interval 14.7% to 33.4%) at 0-13 days and 46.8% (38.7% to 53.8%) at ≥14 days after the second dose. Adjusted vaccine effectiveness against hospital admissions was 55.5% (46.5% to 62.9%) and against deaths was 61.2% (48.9% to 70.5%) at ≥14 days after the second dose. Vaccine effectiveness ≥14 days after the second dose was highest for the youngest age group (70-74 years)—59.0% (43.7% to 70.2%) against symptomatic disease, 77.6% (62.5% to 86.7%) against hospital admissions, and 83.9% (59.2% to 93.7%) against deaths—and declined with increasing age. CONCLUSIONS: Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant. Vaccine protection was, however, low until completion of the two dose regimen, and vaccine effectiveness was observe to decline with increasing age among this elderly population.engBMJ Publishing GroupEffectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCOVID-19CoronaVacVaccine effectivenessGamma variantCase control studyElderlyCOVID-19Vacinas contra COVID-19Estudos de Casos e ControlesIdosoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83128https://www.arca.fiocruz.br/bitstream/icict/48995/1/license.txt0a01a23320286399b52cf17eb1aafb12MD51ORIGINALEffectiveness of the CoronaVac vaccine in older adults.pdfEffectiveness of the CoronaVac vaccine in older adults.pdfapplication/pdf571880https://www.arca.fiocruz.br/bitstream/icict/48995/2/Effectiveness%20of%20the%20CoronaVac%20vaccine%20in%20older%20adults.pdf1ae364a5298295bc71f9e3a5a10c4cb0MD52ve_Albert_Ko_etal_IGM_2021.pdfve_Albert_Ko_etal_IGM_2021.pdfCorrectionsapplication/pdf126969https://www.arca.fiocruz.br/bitstream/icict/48995/4/ve_Albert_Ko_etal_IGM_2021.pdf99e4871c073fde0be23b573ae42cc486MD54TEXTEffectiveness of the CoronaVac vaccine in older adults.pdf.txtEffectiveness of the CoronaVac vaccine in older adults.pdf.txtExtracted texttext/plain67373https://www.arca.fiocruz.br/bitstream/icict/48995/3/Effectiveness%20of%20the%20CoronaVac%20vaccine%20in%20older%20adults.pdf.txt7f4cff7736404e1ed5bacfdf7d0da0b4MD53icict/489952023-03-15 14:33:06.724oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:06Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.en.fl_str_mv |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
title |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
spellingShingle |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study Ranzani, Otavio T. COVID-19 CoronaVac Vaccine effectiveness Gamma variant Case control study Elderly COVID-19 Vacinas contra COVID-19 Estudos de Casos e Controles Idoso |
title_short |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
title_full |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
title_fullStr |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
title_full_unstemmed |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
title_sort |
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study |
author |
Ranzani, Otavio T. |
author_facet |
Ranzani, Otavio T. Hitchings, Matt D. T. Dorion, Murilo D'Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
author_role |
author |
author2 |
Hitchings, Matt D. T. Dorion, Murilo D'Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
author2_role |
author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Ranzani, Otavio T. Hitchings, Matt D. T. Dorion, Murilo D'Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
dc.subject.en.en_US.fl_str_mv |
COVID-19 CoronaVac Vaccine effectiveness Gamma variant Case control study Elderly |
topic |
COVID-19 CoronaVac Vaccine effectiveness Gamma variant Case control study Elderly COVID-19 Vacinas contra COVID-19 Estudos de Casos e Controles Idoso |
dc.subject.decs.pt_BR.fl_str_mv |
COVID-19 Vacinas contra COVID-19 Estudos de Casos e Controles Idoso |
description |
Corrections: In this paper by Ranzani and colleagues (BMJ 2021;374:n2015, doi:10.1136/bmj.n2015, published 20 August 2021), author Edlaine Faria de Moura Villela should have been shown affiliated with address 5 [not 6], the Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil. |
publishDate |
2021 |
dc.date.accessioned.fl_str_mv |
2021-09-06T14:30:38Z |
dc.date.available.fl_str_mv |
2021-09-06T14:30:38Z |
dc.date.issued.fl_str_mv |
2021 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
RANZANI, Otavio T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. British Medical Journal, v. 374, n. 2015, p. 1-12, 20 Aug. 2021. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/48995 |
dc.identifier.issn.pt_BR.fl_str_mv |
1759-2151 |
dc.identifier.doi.pt_BR.fl_str_mv |
10.1136/bmj.n2015 |
dc.identifier.eissn.pt_BR.fl_str_mv |
0959-8138 |
identifier_str_mv |
RANZANI, Otavio T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. British Medical Journal, v. 374, n. 2015, p. 1-12, 20 Aug. 2021. 1759-2151 10.1136/bmj.n2015 0959-8138 |
url |
https://www.arca.fiocruz.br/handle/icict/48995 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
BMJ Publishing Group |
publisher.none.fl_str_mv |
BMJ Publishing Group |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/48995/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/48995/2/Effectiveness%20of%20the%20CoronaVac%20vaccine%20in%20older%20adults.pdf https://www.arca.fiocruz.br/bitstream/icict/48995/4/ve_Albert_Ko_etal_IGM_2021.pdf https://www.arca.fiocruz.br/bitstream/icict/48995/3/Effectiveness%20of%20the%20CoronaVac%20vaccine%20in%20older%20adults.pdf.txt |
bitstream.checksum.fl_str_mv |
0a01a23320286399b52cf17eb1aafb12 1ae364a5298295bc71f9e3a5a10c4cb0 99e4871c073fde0be23b573ae42cc486 7f4cff7736404e1ed5bacfdf7d0da0b4 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009112665948160 |